摘要
目的:对治疗再生障碍性贫血(简称再障)的中药进行网络文献挖掘,借助网络药理学分析健脾药和补肾药治疗再障的作用机制差异。方法:通过中国知网、万方数据库和维普数据库,根据纳入排除标准收集2000年1月1日―2023年12月31日关于中药治疗再障的文章,计算并获取健脾药和补肾药的使用频次。借助中药系统药理学数据库与分析平台(TCMSP)获取中药的活性成分和作用靶点,在化源网核对已获取中药成分的名称,通过Gene Cards、OMIM、TTD数据库获取疾病靶点并与中药成分靶点取交集,在STRING数据库进行蛋白质相互作用,通过DAVID、微生信数据库进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析。结果:通过文献数据挖掘得到治疗再障使用频次较高的健脾药和补肾药。健脾药使用频次最高的有黄芪、白术、山药,补肾药有菟丝子、熟地黄、女贞子。经过筛选和去重后,健脾药得到25个活性成分和176个作用靶点,交集靶点71个;补肾药有16个活性成分和188个作用靶点,交集靶点72个。健脾药和补肾药活性成分的GO和KEGG富集分析结果基本无差异。通过对再障的临床诊疗经验发现,治疗上多为健脾药和补肾药共用,效果也基本无差异。结论:通过网络药理学发现健脾药和补肾药治疗再障的作用机制基本无差异,临床所用中药多具有健脾和补肾的作用。
Objective:To explore the online literature of traditional Chinese medicine for the treatment of aplastic anemia(AA),and analyze the difference of the mechanism of action between spleen strengthening drugs and kidney tonifying drugs in the treatment of AA with the help of network pharmacology.Methods:The articles on the treatment of AA with traditional Chinese medicine were collected from January 1,2000 to December 31,2023 in CNKI,Wanfang database and VIP database according to the inclusion and exclusion cri-teria,and the frequency of use of spleen strengthening drugs and kidney tonifying drugs was calculated.The active ingredients and action targets of traditional Chinese medicine were obtained by TCMSP,the names of the obtained Chinese medicine ingredients were checked in the chemical source network,the disease targets were obtained by GeneCards,OMIM and TTD databases and intersected with the targets of traditional Chi-nese medicine ingredients,and the protein interaction was carried out in the STRING database.GO and KEGG analyses were performed through DAVID and bioinformatics databases.Results:The spleen strengthening drugs and kidney tonifying drugs with high frequency in the treatment of of AA were obtained through literature data mining.The most frequently used spleen strengthening drugs were Huangqi(Astragalus),Baizhu(Atractylodes rhizome),Shanyao(Yam);Kidney tonifying drugs were:Tusizi(Semen cuscuta),Shudihuang(Prepared rehmannia root),Nvzhenzi(Ligustrum).After screening and deweighting,25 active ingredients and 176 action targets of spleen strengthening drugs were obtained,with 71 intersection targets of the two.There were 16 active components and 188 targets of kidney tonifyiny drugs,with 72 intersecting targets.There was no difference between GO and KEGG enrichment analyses of active components of spleen strengthening drugs and kidney tonifying drugs.Through the clinical diagnosis and treatment experience of AA,it was found that the treatment was mostly shared by spleen strengthening drugs and kidney tonifying drugs,and the effect was basically not different.Conclusion:Through network pharmacology,it is found that the mechanism of action of spleen strengthening drugs and kidney tonifying drugs in treating AA is basically the same.The use of traditional Chinese medicine in clinical also has the function of strengthening the spleen and tonifying the kidney.
作者
马国栋
崔思远
MA Guodong;CUI Siyuan
出处
《中医临床研究》
2024年第33期1-5,共5页
Clinical Journal Of Chinese Medicine
基金
山东省医药卫生科技项目(202303041540)。
关键词
再生障碍性贫血
网络药理学
健脾补肾
中药
作用机制
Aplastic anemia
Network pharmacology
Strengthening the spleen and tonifying the kidney
Chinese medicine
Action mechanism
